Eli Lilly also said it has filed for Food and Drug Administration approval of the daily GLP-1 pill, called orforglipron, for ...

Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the ATTAIN-MAINTAIN trial. The Phase 3 study ...

Eli Lilly has shown patients maintained most of their weight loss after switching from injectable GLP-1s to its oral drug ...

Eli Lilly (LLY) stock is in focus as the company posts late-stage trial data to indicate that its obesity pill orforglipron ...

Eli Lilly’s oral pill, orforglipron, helped maintain weight loss in patients switching from injectable versions of GLP-1 ...

Regulators in Europe just backed Novo's heavyweight Wegovy--setting the stage for a head-to-head obesity drug showdown in ...

Zepbound (tirzepatide) and Wegovy (semaglutide) are FDA-approved injectable medications revolutionizing weight management. Both belong to the incretin mimetic drug class but differ in their mechanisms ...

Doctors and groups representing employers said they’re increasingly hearing about companies cutting weight loss drugs out of ...

The best weight loss medication for men includes semaglutide (Ozempic , Wegovy ), tirzepatide (Mounjaro , Zepbound ), and ...

Eli Lilly’s orforglipron pill helps maintain weight loss after Zepbound or Wegovy injections, with FDA review underway. Learn ...